Zydus Lifesciences Ltd

Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.24% on the day, quoting at 23849.9. The Sensex is at 75777.13, down 0.12%. Zydus Lifesciences Ltd has added around 23.94% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.44% in last one month and is currently quoting at 24716, up 0.2% on the day. The volume in the stock stood at 14.03 lakh shares today, compared to the daily average of 23 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1114.05, up 2.08% on the day. Zydus Lifesciences Ltd is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma index.The PE of the stock is 29.59 based on TTM earnings ending March 26.Powered by Capital Market - Live

Zydus Lifesciences and its various subsidiaries has invested balance 9.01 crore for subscription of 90,17,848 equity shares under Tranche 2, 3 and 4 of Torrent Urja 25, representing 22.06% of its paid-up share capital. Pursuant to the same, the transaction of subscription of shares of Torrent Urja 25 is consummated on 19 May 2026. In June 2025 under Tranche 1, the company and its subsidiaries had invested Rs 3.86 crore for subscription of 38,64,792 equity shares of Torrent Urja 25, representing 22.06% of its paid-up share capital.

Profit before exceptional item and tax (PBT) increased 8.75% YoY to Rs 2,057.2 crore in Q4 FY26. During the quarter, the company reported an exceptional item of Rs 397.5 crore, primarily on account of a one-time expenditure related to the Mirabegron litigation settlement. EBITDA stood at Rs 2,554.4 crore in Q4 FY26, registering the growth of 20.2% compared with Rs 2,125.5 crore in Q4 FY25. EBITDA margin improved to 33.7% in Q4 FY26 as against 32.6% in Q4 FY25. The company's organic capital expenditure for the quarter stood at Rs 357.7 crore. Revenue from India formulation business jumped 14% YoY to Rs 1,752.8 crore, contributing 24% to consolidated revenue. Branded business grew faster than the market with 15% YoY growth. North America formulation business registered revenues of Rs 2,952.3 crore, down 6% YoY and accounted for 40% of consolidated revenue. In constant currency terms, the business posted revenue of $323 milion. Revenue from international markets formulation business stood at Rs 804.1 crore, up 45% YoY. The business accounted for 11% of consolidated revenues. The growth was broad-based across regions, led by robust demand in emerging markets and Europe, aided by focused execution Revenue from consumer wellness business climbed 61% YoY to Rs 1,463.3 crore. Domestic business grew by 1.7% YoY. Within the domestic business, the seasonal brands declined by 9.8%, whereas the skin & hair care brands and food & nutrition brands registered 39.7% and 9.4% YoY growth respectively. On full year basis, the company's consolidated net profit jumped 11.37% to Rs 5,040 crore in FY26 compared with Rs 4,525.5 crore in FY25. Revenue from operations increased 16.81% to Rs 27,148.4 crore in FY26 compared with Rs 23,241.5. Meanwhile, the company's board recommended a final dividend of Re 1 per equity share of face value Re 1 each for FY26, subject to shareholders' approval at the forthcoming Annual General Meeting (AGM) scheduled on Tuesday, 11 August 2026. The company has fixed 24 July 2026 as the record date for determining shareholders eligible for the dividend. Further, the board also approved a share buyback of up to 95,65,217 equity shares aggregating up to Rs 1,100 crore at a price of Rs 1,150 per share, representing a premium of 16.02% over the stock's closing price of Rs 991.20 on 18 May 2026. The record date for the buyback has been fixed as 29 May 2026. As on 15 May 2026, promoters and the promoter group held a 74.9950% stake in the company. Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.Powered by Capital Market - Live

Zydus Lifesciences announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Zydus Lifesciences announced that the Annual General Meeting(AGM) of the company will be held on 11 August 2026.

Net profit of Zydus Lifesciences rose 8.68% to Rs 1272.50 crore in the quarter ended March 2026 as against Rs 1170.90 crore during the previous quarter ended March 2025. Sales rose 18.19% to Rs 7434.40 crore in the quarter ended March 2026 as against Rs 6290.20 crore during the previous quarter ended March 2025. ParticularsQuarter EndedMar. 2026Mar. 2025% Var. Sales7434.406290.20 18 OPM %34.3633.79 - PBDT2565.602129.50 20 PBT2057.201891.60 9 NP1272.501170.90 9 Powered by Capital Market - Live

The board of Zydus Lifesciences at its meeting held on 19 May 2026 has approved the proposal to buyback up to 95,65,217 fully paid up equity shares of the company at a price of Rs 1,150 per equity share payable in cash for an aggregate amount not exceeding Rs 1100 crore.

Zydus Lifesciences has 29 May 2026 as record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.

Zydus Lifesciences Ltd is up for a third straight session in a row. The stock is quoting at Rs 1012.55, up 2.1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.4% on the day, quoting at 23783.6. The Sensex is at 75701.49, up 0.4%. Zydus Lifesciences Ltd has risen around 7.82% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has risen around 9.71% in last one month and is currently quoting at 24551.05, up 0.39% on the day. The volume in the stock stood at 13.44 lakh shares today, compared to the daily average of 9.62 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1016.25, up 2.03% on the day. Zydus Lifesciences Ltd is up 12.17% in last one year as compared to a 4.94% drop in NIFTY and a 13.93% drop in the Nifty Pharma index.The PE of the stock is 21.23 based on TTM earnings ending December 25.Powered by Capital Market - Live

Meanwhile, the company's subsidiary, Zydus Worldwide DMCC (Zydus Worldwide) through its wholly owned acquisition subsidiary Zara Merger Sub Inc., has signed a definitive agreement with Assertio Holdings, to acquire all outstanding shares of Assertio for $ 23.50 per share in cash. The deal represents total consideration of approximately $166.4 million on a fully-diluted basis, calculated using the treasury stock method. Assertio is a U.S. based pharmaceutical company focused on specialty and oncology supportive-care therapies with its novel product ROLVEDON (eflapegrastim xnst), approved by USFDA for long-acting G CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. Its turnover was $ 68.23 million in current year 2025. This transaction will help Zydus to secure an immediate U.S. specialty oncology commercial footprint in the U.S and serves as a platform to expand its oncology specialty portfolio. Assertio's over 170 community oncology accounts and buy-and-bill infrastructure are expected to strengthen Zydus' oncology platform. Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction will be followed by a merger, subject to customary closing conditions, including the tender of a majority of Assertio's outstanding shares. Subsequently, Zydus will acquire the untendered shares through a second-step merger at the same offer price. The tender offer is expected to commence within five business days following the date of the merger agreement. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions. Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. On a consolidated basis, Zydus Lifesciences' net profit rose 1.82% to Rs 1042.10 crore while net sales rose 32.34% to Rs 6780.40 crore in Q3 December 2025 over Q3 December 2024.Powered by Capital Market - Live